168 related articles for article (PubMed ID: 35248783)
21. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
22. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
Chao Y; Fan L; Gao XY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the Prognostic Value and Risk Factors of Early Relapse for Newly Diagnosed Multiple Myeloma Patients in the Era of Novel Agents].
Li QH; Liu Y; Wang J; Wang JJ; Dong F; Yang P; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):148-153. PubMed ID: 36765492
[TBL] [Abstract][Full Text] [Related]
26. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
[TBL] [Abstract][Full Text] [Related]
28. Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
[TBL] [Abstract][Full Text] [Related]
29. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics and Prognostic Analysis of Multiple Myeloma with Extramedullary Disease: A SEER-Based Study.
Li G; Song YP; Lv Y; Li ZZ; Zheng YH
J Oncol; 2021; 2021():6681521. PubMed ID: 33603785
[TBL] [Abstract][Full Text] [Related]
31. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
32. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].
Geng CY; Yang GZ; Wang GR; Wang HJ; Zhou HX; Zhang ZY; Jian Y; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):390-395. PubMed ID: 34218581
[No Abstract] [Full Text] [Related]
33. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Zamagni E; Patriarca F; Nanni C; Zannetti B; Englaro E; Pezzi A; Tacchetti P; Buttignol S; Perrone G; Brioli A; Pantani L; Terragna C; Carobolante F; Baccarani M; Fanin R; Fanti S; Cavo M
Blood; 2011 Dec; 118(23):5989-95. PubMed ID: 21900189
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
[No Abstract] [Full Text] [Related]
36. [The Prognostic Value of Early Relapse after Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma].
Tian WW; Ren RR; Zheng FL; Zhu QJ; Gong R; Wang T; Gao ZL; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):535-539. PubMed ID: 33812427
[TBL] [Abstract][Full Text] [Related]
37. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
Song GY; Jung SH; Kim K; Kim SJ; Yoon SE; Lee HS; Kim M; Ahn SY; Ahn JS; Yang DH; Kim HJ; Lee JJ
BMC Cancer; 2020 Aug; 20(1):803. PubMed ID: 32831058
[TBL] [Abstract][Full Text] [Related]
38. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
39. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases.
Chen Q; Zheng X; Lin Q; Chen J
Ann Clin Lab Sci; 2023 Jan; 53(1):14-20. PubMed ID: 36889774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
